Free Trial
NASDAQ:HRTX

Heron Therapeutics (HRTX) Stock Price, News & Analysis

Heron Therapeutics logo
$1.40 +0.08 (+6.06%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.44 +0.04 (+2.79%)
As of 08/22/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Heron Therapeutics Stock (NASDAQ:HRTX)

Key Stats

Today's Range
$1.33
$1.42
50-Day Range
$1.28
$2.23
52-Week Range
$1.04
$2.68
Volume
3.51 million shs
Average Volume
2.33 million shs
Market Capitalization
$214.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Hold

Company Overview

Heron Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

HRTX MarketRank™: 

Heron Therapeutics scored higher than 84% of companies evaluated by MarketBeat, and ranked 173rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Heron Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Heron Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Heron Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Heron Therapeutics are expected to grow in the coming year, from ($0.13) to ($0.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Heron Therapeutics is -70.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Heron Therapeutics is -70.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Heron Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    24.43% of the float of Heron Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Heron Therapeutics has a short interest ratio ("days to cover") of 22.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Heron Therapeutics has recently decreased by 0.17%, indicating that investor sentiment is improving.
  • Dividend Yield

    Heron Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Heron Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.43% of the float of Heron Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Heron Therapeutics has a short interest ratio ("days to cover") of 22.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Heron Therapeutics has recently decreased by 0.17%, indicating that investor sentiment is improving.
  • News Sentiment

    Heron Therapeutics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Heron Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    7 people have searched for HRTX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Heron Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,230,656.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.86% of the stock of Heron Therapeutics is held by insiders.

  • Percentage Held by Institutions

    80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Heron Therapeutics' insider trading history.
Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Stock News Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
Heron Therapeutics Announces Strategic Financial Initiatives
See More Headlines

HRTX Stock Analysis - Frequently Asked Questions

Heron Therapeutics' stock was trading at $1.53 at the beginning of 2025. Since then, HRTX shares have decreased by 8.5% and is now trading at $1.40.

Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings results on Friday, August, 8th. The biotechnology company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01. The biotechnology company had revenue of $37.20 million for the quarter, compared to the consensus estimate of $38.08 million.
Read the conference call transcript
.

Heron Therapeutics subsidiaries include Heron Therapeutics B.V..

Heron Therapeutics' top institutional investors include Palisade Capital Management LP (3.32%), Tejara Capital Ltd (2.95%), Geode Capital Management LLC (2.34%) and AIGH Capital Management LLC (1.97%). Insiders that own company stock include Rubric Capital Management Lp, Adam Morgan, Craig A Collard, Ira Duarte and William P Forbes.
View institutional ownership trends
.

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/08/2025
Today
8/23/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HRTX
CIK
818033
Employees
300
Year Founded
1983

Price Target and Rating

High Price Target
$6.00
Low Price Target
$3.00
Potential Upside/Downside
+221.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.58 million
Net Margins
-0.62%
Pretax Margin
-0.62%
Return on Equity
N/A
Return on Assets
-0.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.82
Quick Ratio
0.53

Sales & Book Value

Annual Sales
$144.29 million
Price / Sales
1.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.18) per share
Price / Book
-7.78

Miscellaneous

Outstanding Shares
153,290,000
Free Float
144,309,000
Market Cap
$214.61 million
Optionable
Optionable
Beta
1.15

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:HRTX) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners